Novo Nordisk A/S v. Caraco Pharmaceutical, No. 11-1223 (Fed. Cir. June 18, 2013)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Novo Nordisk A/S and Novo Nordisk Inc. (“Novo”) a p- peal a decision of the United States District Court for the Eastern District of Michigan which held that claim 4 of U.S. Patent No. 6,677,358 (“’358 patent”) was invalid as obvious and that the ’358 patent was unenforceable due to inequitable conduct. See Novo Nordisk A/S v. Caraco Pharm. Lab s., 775 F. Supp. 2d 985, 1025 (E.D. Mich. 2011). For the reasons set forth below, we affirm in part and reverse in part. I.